
|Articles|August 12, 2014 (Updated: April 18, 2020)
- Gastrointestinal Cancers (Issue 2)
- Volume 2
- Issue 1
Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC
Author(s)Paulo Marcelo Hoff, MD, PhD, FACP
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).
Learn about adverse events associated with regorafenib for mCRC > >
Articles in this issue
over 11 years ago
An Analysis of Bevacizumab or Cetuximab for CRCover 11 years ago
The Importance of Testing for BRAF Status in CRC Patientsover 11 years ago
Proactive Management of Regorafenib-Associated AEsover 11 years ago
Survival Benefit Confirmed With Palliative Resection in mCRCRelated Content
Advertisement



mFOLFOX/Bevacizumab/Atezolizumab Improves PFS in dMMR/MSI-H Colorectal Cancer
Published: | Updated:





























